NFYA and CCNA2

Data Source:
BioGRID (pull down)

		NFYA	CCNA2
Description		nuclear transcription factor Y subunit alpha	cyclin A2
Image
GO Annotations	Cellular Component	Chromatin Nucleus Nucleoplasm CCAAT-binding Factor Complex Protein-DNA Complex RNA Polymerase II Transcription Regulator Complex	Cyclin-dependent Protein Kinase Holoenzyme Complex Female Pronucleus Male Pronucleus Nucleus Nucleoplasm Cytoplasm Cytosol Cyclin A2-CDK2 Complex
	Molecular Function	Transcription Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific DNA Binding DNA-binding Transcription Factor Activity Protein Binding	Protein Binding Cyclin-dependent Protein Serine/threonine Kinase Regulator Activity Protein Kinase Binding Protein Domain Specific Binding
	Biological Process	Regulation Of Transcription, DNA-templated Regulation Of Transcription By RNA Polymerase II Transcription By RNA Polymerase II Regulation Of Cholesterol Biosynthetic Process Positive Regulation Of Transcription, DNA-templated Rhythmic Process	Regulation Of Cyclin-dependent Protein Serine/threonine Kinase Activity G2/M Transition Of Mitotic Cell Cycle Regulation Of DNA Replication Ras Protein Signal Transduction Viral Process Histone Phosphorylation Protein Deubiquitination Animal Organ Regeneration Response To Glucagon Cellular Response To Platelet-derived Growth Factor Stimulus Cellular Response To Leptin Stimulus Mitotic Cell Cycle Phase Transition Cell Cycle G1/S Phase Transition Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fibroblast Proliferation Cell Division Cellular Response To Cocaine Cellular Response To Luteinizing Hormone Stimulus Cellular Response To Estradiol Stimulus Cellular Response To Hypoxia Cellular Response To Nitric Oxide Cochlea Development Cellular Response To Insulin-like Growth Factor Stimulus
Pathways		PPARA activates gene expression Activation of gene expression by SREBF (SREBP) Activation of gene expression by SREBF (SREBP) ATF4 activates genes in response to endoplasmic reticulum stress ATF6 (ATF6-alpha) activates chaperone genes ATF6 (ATF6-alpha) activates chaperone genes FOXO-mediated transcription of cell death genes	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 G0 and Early G1 Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes Telomere Extension By Telomerase Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 Senescence-Associated Secretory Phenotype (SASP) DNA Damage/Telomere Stress Induced Senescence Ub-specific processing proteases Processing of DNA double-strand break ends TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation G2 Phase Orc1 removal from chromatin CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition p53-Dependent G1 DNA Damage Response Cyclin A:Cdk2-associated events at S phase entry
Drugs			4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine 6-O-Cyclohexylmethyl Guanine [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE Variolin B
Diseases
GWAS		Mean spheric corpuscular volume ( 32888494) White blood cell count ( 27863252)	Mean corpuscular hemoglobin ( 32888494)
Interacting Genes		48 interacting genes: APP APPBP2 ATF6 ATF6B ATXN1 BANP BRCA1 CCNA2 CDC25A CDK2 CDKN1A CEBPA CSNK2A1 DVL3 E2F6 ELF1 GTF2A1 HMGA1 JUN KPNB1 LUC7L2 NFYB NFYC NR5A1 PAPOLG POGZ POU2F1 POU3F2 PWP1 QRICH1 SP1 SPI1 SREBF2 SRF SRSF1 TAF11 TAF12 TAF6 TCAF1 TP53 UBL5 USF1 USF2 VEZF1 ZC3H10 ZHX1 ZHX2 ZHX3	49 interacting genes: ARID4A BRCA1 BRCA2 BTG1 BUB1B CALM1 CDC20 CDC25C CDC6 CDK1 CDK2 CDK3 CDKN1A CDKN1B CDT1 DTNBP1 E2F1 E2F3 FANCC FEN1 H1-1 H1-5 HERC5 HIRA ITGB3BP KAT2B MAD2L1 MAGEA11 MYBL2 NFYA PGR POLA1 PRC1 PSMD4 PTMA RAD23A RB1 RBL1 RBL2 RPA1 SKP1 SKP2 SP1 TAF1 TP53 TRAF3IP1 UBE2C UBTF USP37
Entrez ID		4800	890
HPRD ID		01793	00453
Ensembl ID		ENSG00000001167	ENSG00000145386
Uniprot IDs		A0A024RD22 P23511	P20248
PDB IDs		4AWL 6QMP 6QMQ 6QMS	1E9H 1FIN 1FVV 1GY3 1H1P 1H1Q 1H1R 1H1S 1H24 1H25 1H26 1H27 1H28 1JST 1JSU 1OGU 1OI9 1OIU 1OIY 1OKV 1OKW 1OL1 1OL2 1P5E 1PKD 1QMZ 1URC 1VYW 2BKZ 2BPM 2C4G 2C5N 2C5O 2C5V 2C5X 2C6T 2CCH 2CCI 2CJM 2I40 2IW6 2IW8 2IW9 2UUE 2UZB 2UZD 2UZE 2UZL 2V22 2WEV 2WFY 2WHB 2WIH 2WIP 2WMA 2WMB 2WPA 2WXV 2X1N 3EID 3EJ1 3EOC 3F5X 4BCK 4BCM 4BCN 4BCP 4CFM 4CFN 4CFU 4CFV 4CFW 4CFX 4EOI 4EOJ 4EOK 4EOL 4EOM 4EON 4EOO 4EOP 4EOQ 4EOR 4EOS 4FX3 5CYI 5IF1 5LMK 5NEV 6ATH 6GVA 6P3W 6Q6G 6Q6H 6RIJ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?